Psoriasis
main-banner
Psoriasis
TAK-279-3001 Enrolling

Plaque Psoriasis Study (60 Weeks)


Treatment: Oral Age: 18 Years


Who Can Participate?

Adults (18+) with chronic plaque psoriasis (PSO) may participate.

Inclusion Criteria

  • A diagnosis of chronic PSO for at least 6 months
  • Moderate-to-severe PSO
  • PSO covering at least 10% of BSA (body surface area)*
  • Be a candidate for phototherapy or systemic therapy

*1% of your body surface is roughly equal to the palm of your hand (no wrists or fingers).

What Are The Benefits?

  • No cost to participate or receive treatment
  • Regular visits with study doctors who specialize in treating PSO (18 visits)
  • Will receive either an investigative oral treatment (study drug) or a placebo
  • Reimbursement for study-related expenses may be provided

How Long Will The Study Last?

  • 60 Weeks

Participating Locations

Participating Experts

Dr. David N. Adam

Dermatologist

Dr. Lorne Albrecht

Dermatologist

Dr. Carsten Hamann

Dermatologist

Dr. Dathan Hamann

Dermatologist

Dr. Sameh Hanna

Dermatologist

Dr. Firouzeh Niakosari

Dermatologist

Dr. Marisa Ponzo

Dermatologist

Dr. Les A. Rosoph

Dermatologist

Dr. Dusan Sajic

Dermatologist

Dr. G. Daniel Schachter

Dermatologist

Dr. Matthew Zirwas

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: April 07, 2024

Official Title

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis

ClinicalTrials.gov ID

NCT06088043

Sponsor

Takeda

Study Description

  • Brief Summary:

    The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.

  • Condition or Disease:

    Plaque Psoriasis

  • Intervention/Treatment:

    Drug: TAK-279
    Drug: Placebo
    Drug: Apremilast
  • Phase:

    Phase 3

  • Ages Eligible for Study:

    18 Years and older (Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

Plaque psoriasis for at least 6 months.
Moderate to severe disease.
Candidate for phototherapy or systemic therapy.

Exclusion Criteria:

Other forms of psoriasis.
History of recent infection.
Prior exposure to TAK-279 or active comparator.

Other protocol defined inclusion/exclusion criteria apply.


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Psoriasis

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content